Welcome to our dedicated page for Promis Neuroscie news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on Promis Neuroscie stock.
Promis Neurosciences (PMN) is a clinical-stage biotechnology company pioneering precision antibody therapies targeting toxic misfolded proteins in neurodegenerative diseases. This page provides investors and researchers with timely updates on PMN's scientific advancements, clinical trial progress, and strategic developments.
Access comprehensive coverage of material events including regulatory milestones, research publications, and partnership announcements. Our curated news collection helps stakeholders track PMN's progress in developing treatments for Alzheimer's, ALS, and related disorders through its proprietary ProMIS™ discovery platform.
Key updates include clinical trial phase transitions, intellectual property developments, and peer-reviewed data disclosures. Bookmark this page for direct access to verified press releases and objective analysis of PMN's position in the neurodegenerative therapeutics landscape.
ProMIS Neurosciences (NASDAQ: PMN), a clinical-stage biotech company focused on neurodegenerative diseases, has secured total financing of $9.2 million through multiple channels. This includes a $2.4 million private placement through warrant sales at $0.1875 per share, $6.8 million from existing warrant exercises, and $0.8 million from a registered offering.
The new warrants have an exercise price of $1.25 per share with a five-year expiration term. The private placement, expected to close on July 24, 2025, received support from an existing healthcare-focused institutional investor. Funds will support the clinical development of PMN310, the company's lead therapeutic candidate, and general corporate expenses.
ProMIS Neurosciences (NASDAQ: PMN), a clinical-stage biotech company focused on neurodegenerative diseases, has announced a $0.8 million registered direct offering through the sale of pre-funded warrants. The company will issue 984,736 pre-funded warrants at $0.8124 per share to an existing healthcare-focused institutional investor.
The warrants will have a nominal exercise price of $0.0001 per share and will be immediately exercisable. The offering is expected to close around July 24, 2025. Proceeds will support the clinical development of PMN310, the company's lead therapeutic candidate, and provide working capital for general corporate expenses.
ProMIS Neurosciences (NASDAQ: PMN) has received Fast Track designation from the FDA for PMN310, its lead therapeutic candidate for Alzheimer's disease treatment. This designation accelerates development for therapies addressing serious unmet medical needs and enables enhanced FDA engagement.
PMN310 is designed to selectively target toxic forms of amyloid-beta, potentially offering reduced side effects compared to current treatments, particularly regarding ARIA (brain swelling and bleeding). The company is currently conducting the PRECISE-AD Phase 1b trial, with interim data expected in Q2 2026 and final results in Q4 2026.
ProMIS Neurosciences (Nasdaq: PMN) reported its 2024 financial results and key developments. The company successfully initiated a 100-patient Phase 1b clinical trial for PMN310, their lead antibody candidate for Alzheimer's disease. The PRECISE-AD trial is currently enrolling and dosing patients across 22 US sites, with interim results expected in 1H 2026 and topline results by end of 2026.
Financial highlights include cash position of $13.3 million as of December 31, 2024, and completion of a PIPE financing providing $30.3 million upfront with potential for additional $92.4 million from warrant exercises. The company reported net income of $2.8 million for 2024, primarily due to a $22.6 million gain from warrant liability changes. R&D expenses increased to $10.6 million, while G&A expenses slightly decreased to $6.2 million.
The company expanded its IP portfolio with 23 newly granted patents, including 17 for PMN310. They also advanced programs in ALS and Parkinson's disease, identifying PMN440 as a lead vaccine candidate for multiple synucleopathies.
ProMIS Neurosciences (Nasdaq: PMN) announced plans to present preclinical data at the 2025 AD/PD International Conference in Vienna. The company will showcase three key presentations focusing on their platform-derived antibodies and vaccines for neurodegenerative diseases.
The presentations include: (1) A study on Alzheimer's vaccine design showing that immunization with peptide 301 produced maximal reactivity against AD brain oligomers; (2) Research on alpha-synuclein vaccine optimization for treating conditions like Parkinson's disease, demonstrating high-affinity antibodies with selectivity for pathogenic ASyn; and (3) Development of selective antibodies targeting misfolded TDP-43 for treating ALS, frontotemporal dementia, and AD.
The virtual oral presentations will be available on demand starting April 1, 2025, at 7:00am CET.
ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on computationally-derived vaccines for neurodegenerative diseases at the American Academy of Neurology Annual Meeting (April 5-9, 2025) in San Diego.
The company will showcase two key presentations: First, a study on Alzheimer's vaccine optimization showing that immunization with peptide 301 produced maximal reactivity against AD brain oligomers. Second, research on a vaccine for synucleinopathies demonstrating that vaccination with conformational B cell epitopes generated high-affinity antibodies selective for pathogenic alpha-synuclein.
The research focuses on targeting toxic misfolded proteins in conditions like Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company's approach aims to develop vaccines that specifically target toxic amyloid-beta oligomers for AD and pathogenic species of alpha-synuclein for MSA and other synucleinopathies.
ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company specializing in antibody therapeutics for neurodegenerative diseases, has announced its participation in the 37th Annual Roth Conference. Neil Warma, the company's CEO, will engage in a fireside chat on March 18, 2025 at 8:00 a.m. PT in Dana Point, CA.
The company focuses on developing treatments targeting toxic misfolded proteins in three main areas:
- Alzheimer's disease (AD)
- Amyotrophic lateral sclerosis (ALS)
- Multiple system atrophy (MSA)
A live webcast of the presentation will be available on the Events page of ProMIS Neurosciences' website and will remain accessible for at least 30 days after the event.
ProMIS Neurosciences has begun dosing multiple patients in its Phase 1b PRECISE-AD trial for Alzheimer's disease, marking a significant milestone for the company. The trial is evaluating PMN310, a humanized monoclonal antibody designed to selectively target toxic amyloid-beta oligomers while avoiding binding to monomers and amyloid plaques.
This selective targeting approach potentially differentiates PMN310 from other Alzheimer's treatments on the market or in development, with the goal of delivering a more effective and well-tolerated therapy. The rapid enrollment underscores the urgent unmet need for better Alzheimer's treatments.
The company expects six-month interim results in the first half of 2026, with topline results anticipated in the second half of 2026. Trial investigators highlighted that current Alzheimer's treatments offer only modest efficacy and often come with significant side effects like ARIA.
FAQ
What is the current stock price of Promis Neuroscie (PMN)?
What is the market cap of Promis Neuroscie (PMN)?
